Navigation Links
WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
Date:6/28/2009

SHANGHAI, June 29 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had been selected by China's Ministry of Commerce to the list of Top Ten Leading Outsourcing Enterprises in China. The list was announced at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June 23 and 24, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

According to the ministry, revenue generated by Chinese outsourcing companies in 2008 grew 34% year over year to $1.5 billion. The top ten companies produced almost one third of that revenue. Those companies represented the healthcare, service and manufacture, government, education and finance sectors. WuXi PharmaTech was the only winner in healthcare.

"We are honored to receive this recognition by the Ministry of Commerce," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Outsourcing benefits not only China by tapping the skills and talents of our country's productive workforce, but also benefits countries around the world with high-quality, cost-effective products and services provided by outsourcing service companies. We are grateful to the Ministry of Commerce for its generous support of WuXi and the outsourcing industry in general. With continued support, we will continue to develop both capabilities and capacity to better serve the world's leading life science companies."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
2. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
3. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
4. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
5. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
7. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
8. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
11. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... 2016   Merck , a leading science and ... a set of agreements with Evotec AG, whereby Evotec ... genetic reagents such as CRISPR and shRNA libraries. Combining ... an accelerated pathway to explore and identify new drug ... of new targets, a process that can be time- ...
(Date:11/30/2016)... ... 2016 , ... On 28 November 2016, the International Union of Pure and ... moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, 117, and ... the discoverers have been approved by the IUPAC Bureau. The IUPAC Council will be ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
Breaking Biology News(10 mins):